Indication
Head and Neck Carcinoma of Unknown Primary
2 clinical trials
2 products
Clinical trial
HNSALV Trial: Combining Immunotherapy With Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck CancersStatus: Recruiting, Estimated PCD: 2024-12-31
Product
PembrolizumabClinical trial
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck CancerStatus: Recruiting, Estimated PCD: 2025-10-21
Product
Tolinapant